Ulcerative Colitis? Time for a change!!!
The pharmaceutical company Celgene is conducting a new clinical trial for people with ulcerative colitis. The True North Study is determining the safety and effectiveness of an investigational oral drug for adults 18–75 years of age with ulcerative colitis (UC).
WHO MAY QUALIFY?
The study is open to those who meet the following criteria:
· Are 18–75 years of age
· Have a diagnosis of moderate to severe ulcerative colitis
EFCCA Academy - Training Certified Patient Experts
EFCCA is embarking on an exciting new project under the title "EFCCA Academy- Training Certified Patient Experts". The pilot phase will be launched mid 2018.
EFCCA is involved in an exciting project aimed at helping people to ‘live well’ with IBD. We are developing a series of animation videos that will equip people with practical advice and relevant information and hopefully will bring about positive changes to the way they cope with their disease.
In December 2014 the European Crohn’s and Colitis Organisation (ECCO) organised a meeting with IBD Patient Association Representatives and ECCO National Representatives (both nurses and physicians) with the aim to improve patient care and the quality of life for patients with inflammatory bowel disease (IBD). Patients, physicians and nurses were assembled in focus groups and reviewed topics which are of high relevance to patients. The overall outcome of this meeting was that there was an imminent need for patient guidelines.
In the last two years the issue on biologics and biosimilars has received a lot of attention from the medical, regulatory and patient community. Licensing rights of biological medicines used in the treatment not only of IBD but also other autoimmune modulated diseases are coming to an end and biosimilars medicines are being developed to compete with original biological treatment options. In various countries in the EU and elsewhere biosimilars have already entered the market.
The European Summer Camp, or “ESC”, project ran in 2010 and 2011.
